Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals, Inc. develops, manufactures, and distributes generic and specialty pharmaceutical products across various dosage forms and therapeutic areas. The company operates through Generics, Specialty, and AvKARE segments, serving a global market.

56/100 AI Score MCap $4.78B Vol 2.52M

Company Overview

CEOChirag K. Patel
Employees8300
HeadquartersBridgewater, NJ, US
IPO Year2018

Amneal Pharmaceuticals delivers value through its diversified portfolio of generic and specialty pharmaceuticals, targeting significant growth in underserved therapeutic areas. With a robust manufacturing infrastructure and strategic market access, Amneal capitalizes on global healthcare demands, offering investors a compelling opportunity in the pharmaceutical sector.

Investment Thesis

Amneal Pharmaceuticals presents a compelling investment opportunity driven by its diversified business model and strategic focus on high-growth areas within the pharmaceutical industry. The company's Generics segment provides a stable revenue base, while the Specialty segment offers significant growth potential through branded products like Rytary and Emverm. The AvKARE segment ensures consistent sales through government contracts. With a market capitalization of $4.56 billion and a gross margin of 36.8%, Amneal is well-positioned to capitalize on increasing demand for affordable medications and specialized treatments. Key catalysts include successful product launches and expansion into new markets. Investors should consider Amneal for its potential to deliver long-term value through strategic growth initiatives and operational efficiencies.

Key Highlights

  • Market capitalization of $4.56 billion, reflecting substantial investor interest in Amneal's growth potential.
  • Gross margin of 36.8%, indicating efficient cost management and strong pricing strategies.
  • Operates three distinct segments (Generics, Specialty, and AvKARE), providing diversification and revenue stability.
  • Specialty segment focuses on high-margin branded products, offering significant growth opportunities.
  • Global presence with operations in the United States, India, and Ireland, enabling access to diverse markets.

Competitors

Strengths

  • Diversified product portfolio across generics and specialty pharmaceuticals.
  • Established manufacturing infrastructure and supply chain.
  • Strong relationships with government agencies through the AvKARE segment.
  • Global presence with operations in key markets.

Weaknesses

  • High debt levels.
  • Dependence on key products and markets.
  • Exposure to pricing pressures in the generics market.
  • Limited brand recognition compared to larger pharmaceutical companies.

Catalysts

  • Upcoming: Potential FDA approval for new specialty pharmaceutical products.
  • Ongoing: Expansion of the generics product portfolio through strategic acquisitions.
  • Ongoing: Continued growth in the AvKARE segment through government contracts.
  • Ongoing: Successful commercialization of recently launched products.

Risks

  • Potential: Increased competition in the generics market leading to pricing pressures.
  • Potential: Regulatory challenges and delays in product approvals.
  • Ongoing: Dependence on key products and markets.
  • Ongoing: High debt levels impacting financial flexibility.
  • Potential: Patent litigation and intellectual property disputes.

Growth Opportunities

  • Expansion of Specialty Segment: Amneal can drive growth by expanding its portfolio of branded specialty products, particularly in the central nervous system and endocrinology areas. The market for Parkinson's disease treatments, where Rytary is positioned, is expected to grow, offering significant revenue potential. Successful clinical trials and regulatory approvals for new specialty drugs will be critical to capturing market share and enhancing profitability. This segment offers higher margins and less pricing pressure compared to generics.
  • Strategic Acquisitions and Partnerships: Amneal can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. Acquiring companies with complementary product lines or entering into licensing agreements for innovative therapies can accelerate growth and diversify revenue streams. Focusing on niche markets and underserved patient populations can provide a competitive advantage and enhance market positioning. These initiatives can be funded through existing cash reserves and strategic debt financing.
  • Geographic Expansion: Expanding into new international markets, particularly in emerging economies, represents a significant growth opportunity for Amneal. These markets often have unmet medical needs and a growing demand for affordable medications. Establishing distribution networks and securing regulatory approvals in key regions can drive revenue growth and enhance global market presence. This expansion should be carefully managed to ensure compliance with local regulations and cultural nuances.
  • Increased Focus on Complex Generics: Amneal can capitalize on the growing demand for complex generic drugs, such as injectables, ophthalmics, and inhalation products. These products require specialized manufacturing capabilities and face less competition compared to traditional oral solids. Investing in research and development to develop and commercialize complex generics can drive revenue growth and enhance profitability. This strategy aligns with the industry trend towards more sophisticated and higher-value generic products.
  • Leveraging the AvKARE Segment: Amneal can leverage its AvKARE segment to expand its presence in the government healthcare market. The Department of Defense and the Department of Veterans Affairs represent significant opportunities for pharmaceutical and medical product sales. Strengthening relationships with government agencies and securing long-term contracts can provide a stable revenue stream and enhance market visibility. This segment also offers opportunities for cross-selling and bundling of products and services.

Opportunities

  • Expansion of specialty segment through new product launches and acquisitions.
  • Geographic expansion into emerging markets.
  • Increased focus on complex generics and biosimilars.
  • Strategic partnerships and collaborations.

Threats

  • Intense competition in the generics market.
  • Regulatory scrutiny and compliance requirements.
  • Patent expirations and loss of exclusivity.
  • Economic downturns and healthcare reforms.

Competitive Advantages

  • Diversified product portfolio across generics and specialty pharmaceuticals.
  • Established manufacturing infrastructure and supply chain.
  • Strong relationships with government agencies through the AvKARE segment.
  • Global presence with operations in key markets.

About

Founded in 2002 and headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals, Inc. has evolved into a significant player in the pharmaceutical industry. Originally known as Atlas Holdings, Inc., the company rebranded in 2018 to reflect its focus on developing, licensing, manufacturing, and distributing a wide array of generic and specialty pharmaceutical products. Amneal operates through three key segments: Generics, Specialty, and AvKARE. The Generics segment is the cornerstone, producing complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals. The Specialty segment focuses on branded pharmaceuticals targeting central nervous system disorders, endocrinology, and parasitic infections, featuring products like Emverm, Rytary, and Unithroid. The AvKARE segment serves governmental agencies, including the Department of Defense and the Department of Veterans Affairs, providing pharmaceuticals, medical and surgical products, and wholesale distribution services. Amneal sells its products through a network of wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies, extending its reach across the United States, India, Ireland, and other international markets. With 8,300 employees, Amneal is committed to providing accessible and affordable healthcare solutions globally.

What They Do

  • Develops and manufactures generic pharmaceutical products.
  • Creates and markets specialty pharmaceutical products.
  • Produces complex oral solids, injectables, and ophthalmics.
  • Offers treatments for central nervous system disorders and endocrinology.
  • Provides pharmaceuticals and medical products to government agencies.
  • Distributes pharmaceuticals through wholesalers and pharmacies.
  • Operates in the United States, India, and Ireland.

Business Model

  • Develops and manufactures a wide range of generic drugs to offer affordable alternatives to branded medications.
  • Creates and markets branded specialty pharmaceuticals targeting specific therapeutic areas.
  • Generates revenue through the sale of pharmaceutical products to wholesalers, distributors, and government agencies.
  • Utilizes a diversified business model with three segments: Generics, Specialty, and AvKARE.

Industry Context

Amneal Pharmaceuticals operates in the competitive drug manufacturing industry, which is characterized by increasing demand for generic and specialty medications. The global generics market is projected to reach $490 billion by 2027, driven by cost-containment measures and an aging population. The specialty pharmaceuticals market is also growing rapidly, fueled by advancements in biotechnology and personalized medicine. Amneal competes with established players like BHC, DYN, INDV, LNTH, and MIRM, striving to differentiate itself through product innovation, strategic partnerships, and efficient manufacturing processes. The industry faces challenges such as regulatory scrutiny, pricing pressures, and intense competition, requiring companies to adapt and innovate to maintain profitability and market share.

Key Customers

  • Wholesalers and distributors of pharmaceutical products.
  • Hospitals and chain pharmacies.
  • Individual pharmacies.
  • Government agencies, including the Department of Defense and the Department of Veterans Affairs.
AI Confidence: 73% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $785M $2M $0.01
Q2 2025 $725M $22M $0.07
Q1 2025 $695M $12M $0.04
Q4 2024 $731M -$31M $-0.10

Source: Company filings

Chart & Info

Price Chart

Amneal Pharmaceuticals, Inc. (AMRX) stock price: $15.19 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
  • •Community sentiment has shifted positively, with discussions highlighting innovative drug developments and their potential market impact.
  • •Amneal's focus on expanding its generic drug portfolio aligns well with current healthcare trends, positioning the company favorably in a competitive market.
  • •Recent partnerships and collaborations have generated buzz, enhancing the company's reputation and perceived value among investors.

Why Bear

  • •Concerns over regulatory challenges have surfaced, with some analysts questioning the sustainability of Amneal's product pipeline under scrutiny.
  • •Social sentiment reflects skepticism regarding the company's ability to maintain profitability given rising competition in the pharmaceutical sector.
  • •Insider selling activity has raised red flags, suggesting that some stakeholders may lack confidence in the company’s short-term prospects.
  • •Market perception has been tempered by broader economic uncertainties, leading to cautious sentiment surrounding pharmaceutical investments.

Latest News

Technical Analysis

bullish Trend
RSI(14)
63.9
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for AMRX including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Amneal Pharmaceuticals, Inc. (AMRX) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for AMRX.

Make a Prediction

Set your price target for Amneal Pharmaceuticals, Inc. (AMRX), choose a timeframe, and track your prediction accuracy.

Current price: $15.19

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMRX.

Price Targets

Low
$15.00
Consensus
$15.00
High
$15.00

Median: $15.00 (-1.3% from current price)

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

56/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 16.7% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 6/100

    Gross margin of 36.8% is acceptable but leaves limited room for R&D and marketing investment.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 8/100

    Strong cash reserves of $111M provide a solid financial cushion for growth investments and market downturns.

  • R&D Intensity 5/100

    R&D spending at 6.8% of revenue is moderate, balancing current profitability with future development.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 10/100

    Daily turnover of 2.55% indicates healthy liquidity with smooth entry/exit for investors.

  • Price Momentum 6/100

    Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates AMRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Amneal Pharmaceuticals, Inc. do?

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company that develops, manufactures, and distributes a broad range of generic and specialty pharmaceutical products. The company operates through three segments: Generics, which focuses on affordable alternatives to branded medications; Specialty, which develops and markets branded pharmaceuticals targeting specific therapeutic areas; and AvKARE, which provides pharmaceuticals and medical products to government agencies. Amneal's diversified business model and global presence position it as a key player in the pharmaceutical industry, addressing the growing demand for accessible and affordable healthcare solutions.

Is AMRX stock a good buy?

AMRX stock presents a mixed investment profile. The company's diversified business model, with its Generics, Specialty, and AvKARE segments, provides a degree of stability. However, the company's high P/E ratio of 773.17 and modest profit margin of 0.2% warrant caution. Growth opportunities in the specialty segment and strategic acquisitions could drive future value. Investors should weigh these factors against the risks of competition, regulatory challenges, and debt levels. A thorough analysis of financial performance and growth prospects is essential before making an investment decision.

What are the main risks for AMRX?

Amneal Pharmaceuticals faces several key risks. Intense competition in the generics market could lead to pricing pressures and reduced profitability. Regulatory challenges and delays in product approvals could impact the company's ability to launch new products and expand its market share. High debt levels could limit financial flexibility and increase borrowing costs. Dependence on key products and markets could expose the company to revenue volatility. Patent litigation and intellectual property disputes could also pose a threat to the company's long-term growth prospects. Careful monitoring of these risks is crucial for investors.

Is AMRX a good stock to buy?

Whether AMRX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the AMRX MoonshotScore?

The MoonshotScore for AMRX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is AMRX data updated?

AMRX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to AMRX is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for AMRX?

Growth catalysts for Amneal Pharmaceuticals, Inc. (AMRX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Amneal Pharmaceuticals, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are AMRX's main competitors?

Amneal Pharmaceuticals, Inc. (AMRX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether AMRX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about AMRX?

Wall Street analyst coverage for AMRX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is AMRX's market cap?

Market capitalization (market cap) for AMRX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows AMRX's current market cap alongside enterprise value and other valuation metrics.

How has AMRX stock performed recently?

AMRX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing AMRX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in AMRX?

Key risk categories for AMRX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures AMRX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling AMRX?

Insider trading activity for AMRX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is AMRX a good stock for beginners?

Amneal Pharmaceuticals, Inc. (AMRX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is AMRX for first-time investors?

Every stock carries risk, including Amneal Pharmaceuticals, Inc. (AMRX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like AMRX.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Stock data pending update.
Data Sources
profilefundamentalsexistingCopy